Table 3 Performance of the ADNEX model in discriminating between benign and malignant tumours at progressive cut-offs for probability of malignancy
Cut-off | AUC (95% CI) | Sensitivity (95% CI) (%) | Specificity (95% CI) (%) | PPV (95% CI) (%) | NPV (95% CI) (%) | LR+ (95% CI) | LR- (95% CI) | DOR |
|---|---|---|---|---|---|---|---|---|
3% | – | 97.51 (95.02–99.50) | 69.49 (64.87–74.10) | 62.22 (58.70–66.01) | 98.22 (96.55–99.63) | 3.20 (2.75–3.72) | 0.04 (0.02–0.09) | 80.00 |
5% | – | 92.04 (88.05–95.52) | 87.95 (84.62–91.03) | 79.83 (75.30–84.16) | 95.54 (93.33–97.49) | 7.64 (5.82–10.02) | 0.09 (0.06–0.15) | 84.89 |
10% | – | 88.06 (83.58–92.54) | 94.10 (91.79–96.41) | 88.61 (84.54–92.57) | 93.92 (91.71–96.05) | 14.93 (10.01–22.26) | 0.13 (0.09–0.18) | 114.85 |
15% | – | 87.56 (82.59–92.04) | 95.90 (93.85–97.69) | 91.75 (88.02–95.31) | 93.75 (91.57–95.84) | 21.36 (13.18–34.61) | 0.13 (0.09–0.19) | 164.31 |
39.2%a | 0.97 (0.96–0.98) | 87.06 (82.09–93.03) | 97.69 (91.03–99.23) | 95.03 (84.07–98.35) | 93.66 (91.41–96.24) | 37.69 (18.09–78.53) | 0.13 (0.09–0.19) | 289.92 |